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ar  Editor,
e  administration  of  remote  location  anesthesia,  anal-
sia,  and  sedation  practices  to  pregnant  patients  has
reased  in  recent  years.  Psychiatric  disorders  emerging  or
ccurring  during  pregnancy  may  cause  severe  problems
Choosing  an  anesthetic  agent  that  has  no  maternal  or
fetal  toxic  effects  is  important  in  remote  location  anes-
thesia  for  pregnant  women.  In  terms  of  teratogenic  risk,
ECT  use  in  pregnancy  is  considered  relatively  safe.  Propofol
and  methohexital  are  commonly  used  anesthetic  drugs  for
ECT.  The  teratogenic  effects  related  to  these  drugs  have  not
been  speciﬁed.2 Propofol  seems  to  be  associated  with  some
advantages  in  ECT  practice,  including  lower  rises  in  blood
pressure  and  heart  rate  and  faster  postictal  recovery  in  some
measures.3 Succinylcholine  is  often  used  as  a  neuromuscular
block  during  ECT.2 Succinylcholine  is  not  transfered  to  any
extent  across  the  placenta,  and  has  little  effect  on  the  fetus.
The  amount  of  succinylcholine  that  crosses  the  placental
barrier  depends  on  the  concentration  inclination  between
the  maternal  and  fetal  circulation;  thus,  repeated  high  doses both  the  woman  and  the  fetus.  Psychotropic  drugs  used
the  treatment  of  psychiatric  disorders  occurring  during
gnancy  have  side  effects  on  the  mothers  and  fetuses.
e  American  Psychiatric  Association  (APA)  practice  guide-
es  suggest  electroconvulsive  therapy  (ECT)  as  a  primary
atment  for  major  depression  and  bipolar  disorder  dur-
 pregnancy.  ECT  has  been  reported  as  a  treatment  with
h  efﬁcacy  and  low  risk  for  the  management  of  these  dis-
ers  during  all  three  trimesters  of  pregnancy  as  well  as
stpartum.1
These  case  studies  report  our  experience  administer-
 anesthesia  to  four  pregnant  women  with  psychiatric
orders  who  were  scheduled  for  ECT  treatment  during
gnancy.
The  women  undergoing  ECT  treatment  were  diagnosed
th  bipolar  disorder  (two  of  them),  atypical  psychosis,
d  depression.  All  of  the  cases  were  evaluated  by  either
 obstetrician/gynecologist  or  an  anesthesiologist  the  day
fore  treatment.  The  patients  were  monitored  in  the  oper-
ng  room  with  an  electrocardiogram  (ECG),  a  noninvasive
od  pressure  monitor,  and  peripheral  oxygen  saturation
O2).  All  of  the  patients  were  given  oxygen  by  mask  at
6  L/min.  To  prevent  aspiration,  all  of  the  patients  were
en  an  H2-receptor  antagonist  15--20  min  before  the  pro-
dure  and  this  was  continued  throughout  the  operation.
ring  the  process,  the  fetal  heart  rates  were  constantly
ntrolled  with  an  ultrasound  or  doppler  device  by  a  senior
stertics/gynecology  assistant.  The  plasmacholinesterase
els  and  other  routine  blood  values  of  the  patients  were
asured  before  the  procedure.  Propofol  and  Lystenon  were
d  for  anesthesia  induction  and  maintenance  in  all  cases
 mask  ventilation  with  oxygen.  The  mean  age  of  the
tients  was  28  (24--31)  years,  the  mean  gestational  age  was
 weeks  (12--28),  and  the  mean  number  of  ECT  applications
s  10  (8--13).  No  maternal  or  fetal  complications  occurred
rioperatively.  All  of  the  pregnant  women  gave  birth  at
 normal  gestational  age  and  the  average  Apgar  score  of
 newborns  was  between  8  and  10.  No  complications  were
served  in  the  newborns  during  the  one-month  after  birth
or  the  presence  of  atypical  pseudocholinesterase  may  lead
to  newborn  apneas  and  muscle  relaxation.4 In  our  cases,  we
used  propofol  as  a hypnotic  agent  and  succinylcholine  as  a
neuromuscular  block.
All of  the  patients  had  unproblematic  terminations  to
their  pregnancies  and  the  treatment  did  not  have  any
adverse  effects  on  the  babies  or  the  mothers.
Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
References
1. Rabheru K. The use of electroconvulsive therapy in special
patient populations. Can J Psychiatry. 2001;46:710--9.
2. I˙yilikc¸i L, I˙kiz C, Adıyaman E, et al. Remote location anaesthesia:
our experience in pregnant patients (10 cases). Turk J Anaesth
Reanim. 2013;41:65--7.
3. Rasmussen KG. Propofol for ECT anesthesia: a review of the lit-
erature. J ECT. 2014;30:210--5.
4. Maternal & fetal physiology & anesthesia.Morgan GE, Mikhail SM,
Murray JM, editors. Clinical anaesthesiology. 5th ed. New York:
McGraw-Hill Companies; 2013. p. 825--43.
Elif  Dog˘an  Bakıa,∗,  Özlem  C¸etin  Akıcı a,
Halil I˙brahim  Güzelb,  Serdar  Kokulua, Yüksel  Elaa,
Remziye  Gül  Sıvacı a
a Department  of  Anesthesiology  and  Reanimation,
Faculty  of  Medicine,  Afyon  Kocatepe  University,
Afyonkarahisar,  Turkey
b Department  of  Psychiatry,  Faculty  of  Medicine,
Afyon  Kocatepe  University,  Afyonkarahisar,  Turkey
∗ Corresponding  author.
E-mail:  elifbaki1973@mynet.com  (E.D.  Bakı).
Available  online  28  October  2014low-up  period. http://dx.doi.org/10.1016/j.bjane.2014.07.001
